report earn publish note
result initi take quarter issu
report updat model ad addit
thought prgo perform outlook follow recent
meet manag previou revenu estim
vs new estim previou
adjust ep estim vs new estim
lower estim reflect prgo disappoint quarter
lower guidanc rang maintain market
perform rate lower price target
prgo new ep guidanc rang
 vs consensu estim lower
overal revenu guidanc rang
vs consensu estim also lower
adjust oper incom guidanc rang
also provid updat outlook revenu oper
margin three major segment consum healthcar
america chca expect revenu
unchang oper margin approxim
rang estim
revenu oper margin chca consum
healthcar intern chci expect revenu
approxim vs previou expect
oper margin unchang estim
revenu oper margin chci also state
busi grow rang constant
currenc organ basi
updat rx pharma rx guidanc approxim
revenu vs previou expect
oper margin approxim unchang decreas
driven delay new product launch proair
chanc meet manag discuss
among thing headwind face rx pharma segment
strateg review seem intent focu bread
butter consum busi go forward think
solid strategi given volatil gener
believ option rx busi anim health
segment may result potenti catalyst abl spin-off
and/or divest rx busi drag growth still
profit back-to-bas plan may excit mani
given slow growth outlook remain busi think
right strateg move maintain market perform
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report non-gaap adjust ep exclud one-tim item
compani prioriti stock list
compani data secur llc estim reuter
million unless otherwis note
perrigo incom hc hc expens expens incom per specialti
price target
price target base dcf valuat includ discount rate termin
multipl integr larg part outlook carri substanti risk
risk includ turnaround brand consum healthcar busi weak rx
believ share perform market evid emerg recent
turnaround durabl particularli relat eu busi gener busi
recent under-perform
began packag gener home remedi year later one top
over-the-count over-the-counter consum good product compani market share privat label
store brand also among lead compani pharmaceut gener market
well activ pharmaceut ingredi api market
